Answers are grounded in this paper and cite their sources.
Mendelian randomization study shows higher HMGCR expression increases erectile dysfunction risk, suggesting HMGCR inhibitors may provide therapeutic benefit.
Lipid metabolism plays a key role in erectile dysfunction. Our purpose was to evaluate the influence of lipid-lowering drugs on erectile dysfunction employing a two-sample Mendelian randomization (MR) study. Genetic instruments were employed to represent the exposure of lipid-lowering drugs. Inverse variance-weighted MR (IVWMR) was employed to calculate the estimation of effects. IVW-MR analysis showed that the positive relationship between the expression of HMGCR and the risk of erectile dysfunction (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.03-1.57; p = 0.028). No significant relationship was detected between NPC1L1, PSK9 expression and erectile dysfunction. This MR study suggested that HMGCR inhibitors are a more desirable treatment modality for patients with ED.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: